Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 539 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vaccine 3 Clear all
Terminated Phase 1 Interventional

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

NCT01783431
View directory record Official record
Conditions
Melanoma
Interventions
Poly ICLC, leukapheresis
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

NCT01706367
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
C. difficile vaccine, C. difficile vaccine +adjuvant
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

NCT01250795
View directory record Official record
Conditions
Healthy
Interventions
HAI-05 Influenza Vaccine, Saline
Biological · Other
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Wichita, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

NCT02147587
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
36
States / cities
Jonesboro, Arkansas • Los Angeles, California • Santa Maria, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

NCT01364571
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
16
States / cities
Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

NCT04528719
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 79 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
31
States / cities
La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 Vaccine, Placebo
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
50 Years to 64 Years
Enrollment
5,240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
196
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

NCT02561195
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile Vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
17
States / cities
DeLand, Florida • Hollywood, Florida • South Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

NCT00829595
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
Interventions
23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Oct 17, 2026, 5:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

NCT05701800
View directory record Official record
Conditions
Herpes Zoster
Interventions
mRNA-1468, Placebo, Shingrix
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
19
States / cities
Los Angeles, California • Longmont, Colorado • Lakeland, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Interactive Voice Response for COVID-19 Vaccination Training in the Democratic Republic of the Congo

NCT05107479
View directory record Official record
Conditions
COVID-19 Vaccine Knowledge, COVID-19 Vaccine Beliefs
Interventions
COVID-19 Vaccine IVR Training, Control Condition
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8,959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

NCT02864147
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Dysplasia
Interventions
9-valent HPV vaccine, Imiquimod
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 17, 2026, 5:12 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Group Intervention on Vaccine Confidence

NCT05891626
View directory record Official record
Conditions
Vaccination Refusal
Interventions
Group intervention
Behavioral
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Puyallup, Washington
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 17, 2026, 5:12 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

NCT06843317
View directory record Official record
Conditions
RSV Infection
Interventions
Candidate vaccine, SCB-1019T, AREXVY, placebo
Biological · Other
Lead sponsor
Clover Biopharmaceuticals USA, LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

NCT00662272
View directory record Official record
Conditions
Influenza
Interventions
Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine
Biological
Lead sponsor
Colby Pharmaceutical Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

NCT00000958
View directory record Official record
Conditions
HIV Infections
Interventions
MTP-PE/MF59, Env 2-3
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 5:12 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 5:12 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

NCT04957485
View directory record Official record
Conditions
Smallpox
Interventions
Tecovirimat, Smallpox and Mpox Vaccine, Placebo
Drug · Other
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 42 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NasoShield Study of Safety and Immunogenicity

NCT03352466
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NasoShield, BioThrax, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Melbourne, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects

NCT02655549
View directory record Official record
Conditions
Anthrax
Interventions
Px563L, RPA563, or placebo
Biological
Lead sponsor
Pfenex, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Mix and Match With MF59

NCT01317745
View directory record Official record
Conditions
Influenza
Interventions
Phosphate Buffered Saline (PBS) diluent, MF59 Adjuvant, H5N1 Antigen
Other · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Text Reminders to Immunize in a Managed Care Organization

NCT01806714
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Text-based reminder for recommended HPV vaccine or WCC, Non-specific text-based reminder (general health tip)
Other
Lead sponsor
University of Rochester
Other
Eligibility
11 Years to 18 Years
Enrollment
3,812 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 17, 2026, 5:12 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

NCT05327816
View directory record Official record
Conditions
Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
Interventions
RSV preF-based Vaccine, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
11
States / cities
Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 17, 2026, 5:12 AM EDT
Active, not recruiting Phase 3 Interventional

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

NCT05371080
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
3,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 17, 2026, 5:12 AM EDT